

(7)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 45/06	A1	(11) International Publication Number: WO 97/29774 (43) International Publication Date: 21 August 1997 (21.08.97)
<p>(21) International Application Number: PCT/US97/01421</p> <p>(22) International Filing Date: 11 February 1997 (11.02.97)</p> <p>(30) Priority Data: 08/600,655 13 February 1996 (13.02.96) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 08/600,655 (CON) Filed on 13 February 1996 (13.02.96)</p> <p>(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): GREGORY, Susan, A. [US/US]; 4400 Lindell Boulevard #20A, St. Louis, MO 63108 (US). ISAKSON, Peter, C. [US/US]; 2292 Ridgley Woods Drive, Clarkson Valley, MO 63005 (US). ANDERSON, Gary [US/US]; Apartment 311, 1885 McKelvey Hill Drive, Maryland Heights, MO 63043 (US).</p>	<p>(74) Agents: BULOCK, Joseph, W. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, VZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A₄ HYDROLASE INHIBITOR</p>		
<p>(57) Abstract</p> <p>Treatment with a cyclooxygenase-2 inhibitor and a leukotriene A₄ hydrolase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.</p>		